Dr Peter Jandus
Dr Peter Jandus
Human immunoglobulin treatments, delivered either intravenously (IVIG) or subcutaneously (SCIG), play a vital role in managing primary antibody deficiencies (PADs) by preventing bacterial infections. Peter Jandus's research aims to compare immune profiles in PAD patients receiving monthly IVIG versus weekly SCIG, focusing on identifying distinct immune signatures in each group. In prior studies, Dr. Jandus observed that short-term IVIG, irrespective of dose, had no effect on NK cell counts or function, with responses unaffected by common genetic variations in immunodeficiencies. However, his findings suggest that long-term IVIG may influence the innate immune system, especially in cases involving hypogammaglobulinemia and IgG subclass deficiencies.
Additionally, he is developing a research project centered on primary immunodysregulation disorders (PIRD), a subset of inborn errors of immunity characterized by immune regulation defects rather than infection susceptibility. These disorders often involve disruptions in immune tolerance, leading to autoimmunity, autoinflammation, lymphoproliferation, and increased malignancy risk. He is re-evaluating patients with negative genetic tests to identify new pathways and previously undiscovered genetic variants. He also oversees the ESID (European Society for Immunodeficiencies) registry documentation for adults in Geneva. ESID data indicate that 25% of patients with inborn immunity errors initially present with non-infectious symptoms, underscoring the need for broader diagnostic insights and enhanced treatment approaches.
Image title: Inborn Errors of Immunity
EXPERTISE
Peter Jandus specializes in the care of patients with primary immunodeficiencies (inborn errors of immunity), which are rare or “orphan” diseases, as well as acquired immune deficiencies. His experience includes a deep knowledge of subcutaneous and intravenous immunoglobulin therapies and the complexities surrounding genetic testing for immunodeficiencies.
There is an urgent need to enhance current screening methods and functional tests for diagnosing primary and acquired immunodeficiencies, with a focus on identifying both canonical and non-canonical pathways relevant to each patient. His expertise and hands-on experience in these areas aim to bridge these diagnostic gaps and bring more tailored solutions to patients.
FIVE MORE relevant publications
Jandus C, Jandus P. Effects of Intravenous Immunoglobulins on Human Innate Immune Cells: Collegium Internationale Allergologicum Update 2024. Int Arch Allergy Immunol. 2024;185(10):975-996.
Fasshauer M, Borte M, Bitzenhofer M, Pausch C, Pittrow D, Park M, Gladiator A, Jandus P. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases. Adv Ther. 2023;40(12):5168-5187.
Papaserafeim M, Jandus P, Iancu Ferfoglia R, Nieke JP, Vonarburg C, Spirig R, Puga Yung GL, Seebach JD. Effect of intravenous IgG therapy on natural killer cell function related to Fc gamma receptor gene expression. J Allergy Clin Immunol. 2020;146(3):667-670.
Jandus P, Boligan KF, Smith DF, de Graauw E, Grimbacher B, Jandus C, Abdelhafez MM, Despont A, Bovin N, Simon D, Rieben R, Simon HU, Cummings RD, von Gunten S. The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies. Blood. 2019;134(22):1941-1950.
Vigano S, Trabanelli S, Indulsi F, Salomé B, Harari A, Romero P, Helbling A, Jandus C, Jandus P. Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin. J Investig Allergol Clin Immunol. 2017;27(6):394-396